Healeon Medical Names Dr. Robert Alexander As Chief Scientific Officer

NEWBURY PARK, Calif., Aug. 4, 2015 /PRNewswire-iReach/ -- Healeon Medical, Inc. is proud to announce the addition of Dr. Robert Alexander as its Chief Science Officer.  Dr. Alexander brings years of research and clinical-based experience to the Healeon team.  Dr. Alexander will be working closely with Healeon for the development and implementation of IRB clinical trials, along with more defined protocols of use with Healeon's CENTRIcyte 1000 isolation system.

Dr. Alexander holds doctorates in Medicine and Dentistry, and is the author of multiple publications and book chapters on the subject of aesthetic, reconstructive and cranio-maxillofacial surgery, of which he is recipient of many awards and recognitions.  His presentations on the use of high-density platelet-rich plasma concentrates to sports medicine; prolotherapists; and orthopedic-regenerative medicine practitioners, led to important contributions in use of adipose-derived stem/stromal cells with HD PRP for musculoskeletal, wound healing, and regenerative applications.

"We at Healeon Medical are very excited to have Dr. Alexander join our team.  His years of experience in the bio-cellular field bring an immediate impact to Healeon, and allow us to further provide an increased standard-of-care for parties looking to perform point-of-care cellular treatments", said Jeff Greiner, CEO of Healeon Medical. 

With this new relationship, Healeon Medical is setting the standard for which companies in the bio-cellular space should follow.  Now with Dr. Alexander involved, Healeon Medical will be looking to launch a series of IRB clinical trials beginning this summer.

To learn more about Healeon Medical, visit their website at www.healeonmedical.com.

About Healeon Medical, Inc.

Healeon Medical, Inc. (HMI) is a CA based corporation dedicated to paving the way for regenerative solutions by providing innovative medical devices, clinical expertise and support for autologous, point-of-care treatments.  HMI has quickly become the industry leader in the emerging field of regenerative medicine.  The management team is seasoned with over 70 years of medical device and therapy experience and has, in a short period of time, established HMI's CENTRIcyte 1000 as the system of choice for informed clinicians.

Media Contact:Jeff Greiner, Healeon Medical, Inc., 805-499-7482, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Healeon Medical, Inc.
 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.